Literature DB >> 25588889

Distribution of yeast isolates from invasive infections and their in vitro susceptibility to antifungal agents: evidence from 299 cases in a 3-year (2010 to 2012) surveillance study.

Wei Li1, Yu-An Hu, Fang-Qiu Li, Li-Ning Shi, Hai-Feng Shao, Mei Huang, Ying Wang, Dan-Dan Han, Hong Liao, Chun-Fang Ma, Guo-Yong Zhang.   

Abstract

Invasive yeast infections cause significant morbidity and mortality. Surveillance for the infection is necessary to detect trends in species distribution and antifungal resistance. We performed this retrospective study of yeast infection at Jinling Hospital, Nanjing in China, from year of 2010 to 2012. A total of 341 yeast isolates were obtained from patients with invasive infections in the period. Among these isolates, Candida spp. comprised of the highest percentage of yeast strains (91.8 %), followed by Cryptococcus neoformans (5.9 %) and other non-Candida yeast strains (2.3 %). Bloodstream isolates made up 41.3 % of yeast strains and the isolates from CVC made up 17.3 %. Among Candida spp., C. albicans was the most common species identified from non-blood clinical specimens (42.9 %), but appeared in only 20.8 % of blood isolates (P < 0.001). C. tropicalis was the most prevalent Candida species in the blood samples (28.5 %). Candida spp. was mainly isolated from specimens of the ICU patients, while C. neoformans was mainly isolated from specimens in medical wards. Resistance to FLC occurred in 3.7 % of C. albicans, 9.9 % of C. tropicalis, 74.0 % of C. glabrata, and 4.4 % of C. parapsilosis. Most (>92 %) isolates of C. albicans, C. tropicalis, C. parapsilosis, and C. neoformans strains were susceptible to VRC; However, 26.7 % of isolates of C. glabrata were VRC resistant.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25588889     DOI: 10.1007/s11046-015-9858-5

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  37 in total

1.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  Increase in Candida parapsilosis fungemia in critical care units: a 6-years study.

Authors:  Elif Sahin Horasan; Gülden Ersöz; Musa Göksu; Feza Otag; Ahmet Oner Kurt; Sevim Karaçorlu; Ali Kaya
Journal:  Mycopathologia       Date:  2010-06-04       Impact factor: 2.574

3.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; M G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; D L Gibbs
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

Review 4.  Kodamaea ohmeri as an emerging pathogen: a case report and review of the literature.

Authors:  Noura Al-Sweih; Zia U Khan; Suhail Ahmad; Laxmi Devarajan; Seema Khan; Leena Joseph; Rachel Chandy
Journal:  Med Mycol       Date:  2011-03-28       Impact factor: 4.076

Review 5.  Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review.

Authors:  Matthew E Falagas; Nikos Roussos; Konstantinos Z Vardakas
Journal:  Int J Infect Dis       Date:  2010-08-24       Impact factor: 3.623

6.  Prevalent drug resistance among oral yeasts from asymptomatic patients in Hainan, China.

Authors:  Jinyan Wu; Hong Guo; Guohui Yi; Limin Zhou; Xiaowen He; Xianxi Huang; Huamin Wang; Weiling Xue; Jianping Xu
Journal:  Mycopathologia       Date:  2014-05-10       Impact factor: 2.574

Review 7.  History of the development of azole derivatives.

Authors:  J A Maertens
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

8.  Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.

Authors:  María Mercedes Panizo; Vera Reviákina; Maribel Dolande; Sofía Selgrad
Journal:  Med Mycol       Date:  2008-06-27       Impact factor: 4.076

9.  Epidemiology of Invasive Fungal Infections in Latin America.

Authors:  Jose Sifuentes-Osornio; Dora E Corzo-León; L Alfredo Ponce-de-León
Journal:  Curr Fungal Infect Rep       Date:  2012-01-05

10.  Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011.

Authors:  Fang Li; Lin Wu; Bin Cao; Yuyu Zhang; Xiaoli Li; Yingmei Liu
Journal:  BMC Infect Dis       Date:  2013-07-30       Impact factor: 3.090

View more
  3 in total

1.  Epidemiology And Antifungal Susceptibility Patterns Of Invasive Fungal Infections From 2012 To 2014 In A Teaching Hospital In Central China.

Authors:  Hui Xu; Shu-Ying Yu; Meng-Lan Zhou; Ya-Ting Ning; Meng Xiao; Xiao-Gai Li; Meng Chen; Fanrong Kong; Sharon Chen; Liang Ming; Ying-Chun Xu
Journal:  Infect Drug Resist       Date:  2019-11-22       Impact factor: 4.003

Review 2.  Distribution and antifungal susceptibility pattern of Candida species from mainland China: A systematic analysis.

Authors:  Hazrat Bilal; Muhammad Shafiq; Bing Hou; Rehmat Islam; Muhammad Nadeem Khan; Rahat Ullah Khan; Yuebin Zeng
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

3.  Delinking CARD9 and IL-17: CARD9 Protects against Candida tropicalis Infection through a TNF-α-Dependent, IL-17-Independent Mechanism.

Authors:  Natasha Whibley; Jillian R Jaycox; Delyth Reid; Abhishek V Garg; Julie A Taylor; Cornelius J Clancy; M Hong Nguyen; Partha S Biswas; Mandy J McGeachy; Gordon D Brown; Sarah L Gaffen
Journal:  J Immunol       Date:  2015-09-02       Impact factor: 5.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.